利培酮口服液治疗慢性精神分裂症对照研究

A control study of Risperidone oral solution in treating chronic schizophrenia patients

目的:比较利培酮口服液与氯氮平治疗慢性精神分裂症患者的临床疗效及安全性。方法:90例慢性精神分裂症患者随机分成研究组和对照组各45例,分别予以利培酮口服液及氯氮平治疗8周,采用阳性与阴性症状量表(PANSS)、临床总体印象量表(CGI)评定临床疗效,采用不良反应量表(TESS)评定不良反应。结果:治疗8周后利培酮口服液和氯氮平显效率分别为70.5%和73.8%,二者疗效相当,差异无显著性(P>0.05),不良反应发生率利培酮口服液50%、氯氮平90.48%,二者比较差异有显著性(P<0.05)。结论:利培酮口服液治疗慢性精神分裂症有疗效好,不良反应少,安全性高的特点。

Objective ：To compare the efficacy and safety between Risperidone oral solution and Clozapine in the treatment of chronic schizophrenia patients. Methods ：90 patients with chronic schizophrenia were randomly divided into study group （n = 45） and control group （ n = 45）, treated with Risperidone oral solution and Clozapine respectively for 8 weeks. The positive and negative syndomly scale （PANSS）, Clinical Global Impression （CGI） was used to assess the therapeutic efficacy. The treatment emergent symptom scale （TESS） was used to assess side effect. Results： Risperidone oral solution was as effective as Clozapine for the treatment of chronic schizophrenia （ P 〉 0.05 ）. The marked improvement rate of the former was 70.5 % and the later was 73.8 %. The incidence rate of adverse effect was 50% in Risperidone oral solution group and that was 90.48% in Clozapine group. Significant differences were observed between them （ P 〈 0.05 ）. Conclusions： Risperidone oral solution is an effective and safe drug in the treatment of chronic schizophrenia. Its side effects were fewer.